Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Metastasis is a major cause of morbidity and mortality in cancer patients. However, the
molecular and cellular mechanisms underlying the ability of cancer cells to metastasize …

The natural history of small-cell lung cancer (SCLC) includes rapid evolution from
chemosensitivity to chemoresistance, although mechanisms underlying this evolution …

Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast
growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer. However …

Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a
single entity with predictably poor results. Using tumor expression data and non-negative …

Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key
transcription regulators have recently been proposed in cell lines and limited number of …

Lung cancer is the most malignant human cancer worldwide, also with the highest incidence
rate. However, small-cell lung cancer (SCLC) accounts for 14% of all lung cancer cases …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer characterized by
initial chemosensitivity followed by emergence of chemoresistant disease. To study roles for …

Small cell lung cancer (SCLC) is a particular subtype of lung cancer with high mortality.
Recent advances in understanding SCLC genomics and breakthroughs of immunotherapy …

In small cell lung cancer (SCLC), acquired resistance to DNA-damaging therapy is
challenging to study because rebiopsy is rarely performed. We used patient-derived …